FDA approves Dupixent for chronic spontaneous urticaria in young children
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's Dupixent (dupilumab) for the treatment of children (aged 2 to 11 years) with chronic spontaneous urticaria (CSU).
ORIGINAL SOURCE →via Medical Xpress
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · conflict
- [CONFLICT] Intermodal Asia
- [CONFLICT] Securing the Untrusted Agentic Development Layer
- [CONFLICT] Smotrich's October 7 comments should disgust every single one of us - editorial
- [CONFLICT] Backlash grows over Israeli character in R.F. Kuang’s upcoming novel 'Taipei Story'
- [CONFLICT] Australia says Islamic State-linked citizens in Syria camp plan to return home
- [CONFLICT] Toyota Hino debut new Le Series electric MD trucks at ACT Expo